Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Biochem Pharmacol Retrieve available abstracts of 31 articles: HTML format

Single Articles

March 2024
1. DI GIORGIO C, Morretta E, Lupia A, Bellini R, et al
   Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.
   Biochem Pharmacol. 2024;223:116134.
   PubMed     Abstract available
   
   
   February 2024
2. HURRISH KH, Su Y, Patel S, Ramage CL, et al
   Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
   Biochem Pharmacol. 2024;220:115981.
   PubMed     Abstract available
   
   
   November 2023
3. CHIOU JT, Lee YC, Chang LS
   Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition.
   Biochem Pharmacol. 2023 Nov 19:115934. doi: 10.1016/j.bcp.2023.115934.
   PubMed     Abstract available
   
   
   October 2023
4. HAN H, Zhao C, Liu M, Zhu H, et al
   Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia.
   Biochem Pharmacol. 2023 Oct 21:115875. doi: 10.1016/j.bcp.2023.115875.
   PubMed     Abstract available
   
   
   September 2023
5. OIKONOMOU A, Valsecchi L, Quadri M, Watrin T, et al
   High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
   Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809.
   PubMed     Abstract available
   
   
   August 2023
6. CARTER JL, Su Y, Qiao X, Zhao J, et al
   Acquired Resistance to Venetoclax plus Azacitidine in Acute Myeloid Leukemia: in vitro Models and Mechanisms.
   Biochem Pharmacol. 2023 Aug 19:115759. doi: 10.1016/j.bcp.2023.115759.
   PubMed     Abstract available
   
   
   
7. CHIOU JT, Wu YY, Lee YC, Chang LS, et al
   BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
   Biochem Pharmacol. 2023;215:115738.
   PubMed     Abstract available
   
   
   July 2023
8. TOSIC N, Marjanovic I, Lazic J
   Pediatric acute myeloid leukemia: insight into genetic landscape and novel targeted approaches.
   Biochem Pharmacol. 2023 Jul 31:115705. doi: 10.1016/j.bcp.2023.115705.
   PubMed     Abstract available
   
   
   
9. ABDEL-AZIZ AK
   Advances in acute myeloid leukemia differentiation therapy: A critical review.
   Biochem Pharmacol. 2023;215:115709.
   PubMed     Abstract available
   
   
   
10. FRANZA M, Albanesi J, Mancini B, Pennisi R, et al
    The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARalpha and overcomes ATRA resistance in acute promyelocytic leukemia cells.
    Biochem Pharmacol. 2023 Jul 3:115675. doi: 10.1016/j.bcp.2023.115675.
    PubMed     Abstract available
    
    
    
11. AL-ANTARY ET, Gupte A, Carter J, Kaafarani M, et al
    Curing childhood cancer the "Natural" Way: Nature as the source of chemotherapy agents.
    Biochem Pharmacol. 2023;213:115630.
    PubMed     Abstract available
    
    
    May 2023
12. HE C, Peng Z, Zhang D, Guo Y, et al
    Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
    Biochem Pharmacol. 2023;213:115588.
    PubMed     Abstract available
    
    
    April 2023
13. LI Q, Wang M, Liu L
    The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia.
    Biochem Pharmacol. 2023 Apr 4:115539. doi: 10.1016/j.bcp.2023.115539.
    PubMed     Abstract available
    
    
    
14. ZHANG Y, Sultonova RD, You SH, Choi Y, et al
    The anticancer effect of PASylated calreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy.
    Biochem Pharmacol. 2023;210:115473.
    PubMed     Abstract available
    
    
    
15. OU ZY, Wang K, Shen WW, Deng G, et al
    Oncogenic FLT3 internal tandem duplication activates E2F1 to regulate purine metabolism in acute myeloid leukaemia.
    Biochem Pharmacol. 2023;210:115458.
    PubMed     Abstract available
    
    
    March 2023
16. CHIOU JT, Hsu CC, Hong YC, Lee YC, et al
    Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
    Biochem Pharmacol. 2023 Mar 14:115494. doi: 10.1016/j.bcp.2023.115494.
    PubMed     Abstract available
    
    
    January 2023
17. LEE YC, Chiou JT, Chang LS
    AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells.
    Biochem Pharmacol. 2023 Jan 28:115442. doi: 10.1016/j.bcp.2023.115442.
    PubMed     Abstract available
    
    
    October 2022
18. HEGE HURRISH K, Qiao X, Li X, Su Y, et al
    Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
    Biochem Pharmacol. 2022;205:115283.
    PubMed     Abstract available
    
    
    June 2022
19. GUO J, Liu K, Wang J, Jiang H, et al
    A rational foundation for micheliolide-based combination strategy by targeting redox and metabolic circuit in cancer cells.
    Biochem Pharmacol. 2022;200:115037.
    PubMed     Abstract available
    
    
    April 2022
20. GUPTE A, Al-Antary ET, Edwards H, Ravindranath Y, et al
    The Paradox of Myeloid Leukemia Associated with Down Syndrome.
    Biochem Pharmacol. 2022 Apr 25:115046. doi: 10.1016/j.bcp.2022.115046.
    PubMed     Abstract available
    
    
    
21. ZHANG H, Song T, Wang Z, Laura Bonnette U, et al
    Bcr-Abl drives the formation of Hsp70/Bim PPI to stabilize oncogenic clients and prevent cells from undergoing apoptosis.
    Biochem Pharmacol. 2022;198:114964.
    PubMed     Abstract available
    
    
    March 2022
22. LEE YC, Chiou JT, Wang LJ, Chang LS, et al
    Hydroquinone destabilizes BIM mRNA through upregulation of p62 in chronic myeloid leukemia cells.
    Biochem Pharmacol. 2022;199:115017.
    PubMed     Abstract available
    
    
    
23. SUN L, Wang J, Wang Q, He Z, et al
    Pretreatment of umbilical cord derived MSCs with IFN-gamma and TNF-alpha enhances the tumor-suppressive effect on acute myeloid leukemia.
    Biochem Pharmacol. 2022;199:115007.
    PubMed     Abstract available
    
    
    February 2022
24. XING GAO Z, Long Cui Z, Ran Zhou M, Fu Y, et al
    The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.
    Biochem Pharmacol. 2022 Feb 19:114948. doi: 10.1016/j.bcp.2022.114948.
    PubMed     Abstract available
    
    
    
25. XIN Q, Chen Z, Wei W, Wu Y, et al
    Animal Models of Acute lymphoblastic leukemia: recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets.
    Biochem Pharmacol. 2022 Feb 17:114970. doi: 10.1016/j.bcp.2022.114970.
    PubMed     Abstract available
    
    
    October 2021
26. VIGON L, Martinez-Roman P, Rodriguez-Mora S, Torres M, et al
    Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
    Biochem Pharmacol. 2021;192:114666.
    PubMed     Abstract available
    
    
    July 2021
27. LU X, Yan G, Dawood M, Klauck SM, et al
    A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Biochem Pharmacol. 2021 Jul 12:114677. doi: 10.1016/j.bcp.2021.114677.
    PubMed     Abstract available
    
    
    June 2021
28. KIM JH, Lee SJ, Kang KW, Lee BH, et al
    CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Biochem Pharmacol. 2021;190:114658.
    PubMed     Abstract available
    
    
    April 2021
29. WANG F, Huang J, Guo T, Zheng Y, et al
    Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Biochem Pharmacol. 2021 Apr 5:114538. doi: 10.1016/j.bcp.2021.114538.
    PubMed     Abstract available
    
    
    
30. CHIOU JT, Lee YC, Huang CH, Wang LJ, et al
    Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
    Biochem Pharmacol. 2021 Apr 5:114544. doi: 10.1016/j.bcp.2021.114544.
    PubMed     Abstract available
    
    
    January 2021
31. MARENSI V, Keeshan KR, MacEwan DJ
    Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Biochem Pharmacol. 2021;183:114348.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.